Lysosomal enzymes and metabolic activity of polymorphonuclear leukocytes from patients with systemic lupus erythematosus and from experimental animals after levamisole treatment.
The activity of beta-D-glucuronidase (BDG) was lowered and the activity of myeloperoxidase (MPO) was elevated in polymorphonuclear leukocytes (PMNs) of SLE patients compared with normal subjects. After levamisole treatment, the activities of BDG, MPO, and lysozyme rose in PMNs of SLE patients. A higher activity of lysozyme was also observed in peritoneal PMNs of rabbits after levamisole administration. During incubation of human phagocytizing and non-phagocytizing PMNs, no effects of levamisole at concentrations of 10(-3) to 10(-5) M were observed on the release of lysosomal enzymes. These concentrations of levamisole also did not influence INT reductase activity and production of superoxide by normal human PMNs in the presence of zymosan particles. These findings suggest that levamisole might have an effect on the actual level of lysosomal enzymes in PMNs rather than on their release.
D000328:Adult; D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D007978:Levamisole / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000097:blood*; D008247:Lysosomes / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000378:metabolism*; D011817:Rabbits; D013481:Superoxides / Q000378:metabolism; D013997:Time Factors; D015054:Zymosan / Q000494:pharmacology
D001798:Blood Proteins; D013481:Superoxides; D007978:Levamisole; D015054:Zymosan